Biomarker-driven and molecular targeted therapies for colorectal cancers |
| |
| Authors: | Marta Schirripa Stacey A. Cohen Francesca Battaglin Heinz-Josef Lenz |
| |
| Affiliation: | 1. Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy;2. Division of Medical Oncology, University of Washington, Seattle, WA, USA;3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;4. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA |
| |
| Abstract: | Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options. |
| |
| Keywords: | RAS BRAF HER2 Microsatellite instability CpG island methylator phenotype |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
